Heavy Menstrual Bleeding Clinical Trial
Official title:
Identifying the Determinants of Bleeding and Hypermobility in Patients With Heavy Menstrual Bleeding
NCT number | NCT05685199 |
Other study ID # | IDBLEED |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 10, 2024 |
Est. completion date | March 2030 |
In this study, researchers want to learn about the connection between heavy bleeding issues and joint hypermobility (loose joints). They want to know if these issues may indicate other connective tissue problems in girls and women with heavy menstrual bleeding who do not have a known cause. Primary Objective - Compare the severity of heavy menstrual bleeding (HMB) in women with and without Generalized joint Hypermobility Syndrome Disorder/hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS) using bleeding scores. Secondary Objectives - Compare the frequency of co-morbidities in women with and without G-HSD/hEDS.
Status | Recruiting |
Enrollment | 150 |
Est. completion date | March 2030 |
Est. primary completion date | March 2026 |
Accepts healthy volunteers | |
Gender | Female |
Age group | 12 Years to 40 Years |
Eligibility | Inclusion Criteria: - Female - Age 12-40 years - Presence of HMB - Evidence of severe iron-deficiency anemia (hemoglobin level of < 8 g/dL) Exclusion Criteria: - Inability or unwillingness of research participant or legal guardian/representative to give written informed consent. - Current use of anticoagulant and antiplatelet medications - Currently pregnant - Medical conditions that could cause HMB but are not necessarily a bleeding disorder, including, but not limited to: - Uncontrolled hypertension - Documented uterine structural abnormality - Insulin-dependent diabetes mellitus - Chronic kidney disease - Chronic liver disease - Thyroid disease - Documented peripheral arterial disease, venous or arterial vascular events in the past - A structural pathology that would explain the HMB - Presence of a bleeding disorder indicated by prothrombin time, activated partial thromboplastin time, fibrinogen, and von Willebrand factor activity, antigen and factor VIII - Persistent thrombocytopenia as defined by a platelet count of <150,000/uL - If the participant answers "yes" to any of the following questions, they are ineligible: - Could the patient have a known connective tissue disorder? - Family history of sudden death - Family history/personal history of uterine rupture or bowel perforation - Family history/personal history of arterial rupture - Family history/personal history of aneurysm - Family history/personal history of an established EDS diagnosis based on genetic evaluation |
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | Wallace H. Coulter Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Severity of bleeding symptoms in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS): Self-Bleeding Assessment Tool (Self-Bat) | Summary statistics of bleed score including mean, median, standard deviation and range will be reported for women with and without G-HSD/hEDS. The Self-BAT which consist of 14 categories for assessing bleeding symptom will be used. Each of the 14 variables is scored from 0-4 (except CNS bleeding when the scores are 0, 3 and 4) and on the basis of this a final score is derived. Scores of = 3 in children, = 4 in adult males and = 6 in adult females is considered abnormal. | Yearly for 3 years | |
Primary | Number of patients with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS). | The number of patients with G-HSD/hEDS will be reported | Approximately 3 years | |
Primary | Proportion of patients with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS). | The proportion of patients with G-HSD/hEDS will be reported | Approximately 3 years | |
Secondary | Co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS) - PHQ15 | Investigators will compare co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS) using PHQ 15. The PHQ-15 is a subscale of the full Patient Health Questionnaire (PHQ) and screens for 15 somatic symptoms. It scores symptom presence and severity on a 3-point Likert scale (0-2). The total score ranges from 0-30 with higher values indicating increased severity as follows: Minimal (0-4); Low (5-9); Medium (10-14); High (15-30). | Yearly for 3 years | |
Secondary | Co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS): Peds Patient-reported Outcomes Measurement Information System (PROMIS) 49 and Parent Proxy 49 | Investigators will compare co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS) using Peds PROMIS 49 and Parent Proxy 49. The Peds PROMIS 49 is self-reported measures of global, physical, mental, and social health for children (ages 8-17) in the general population and those living with a chronic condition. The Parent Proxy 49 is intended for parents serving as proxy for their child (youth ages 5-17). PROMIS scores are reported as T scores ranging from 0-100. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Anxiety, a T-score of 60 is one SD worse than average. By comparison, an Anxiety T-score of 40 is one SD better than average. However, for positively-worded concepts like Physical Function-Mobility, a T-score of 60 is one SD better than average while a T-score of 40 is one SD worse than average. | Yearly for 3 years | |
Secondary | Co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS): PROMIS 57 | Investigators will compare co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS) using adult PROMIS 57. The PROMIS 57 is for self-reporting measures of global, physical, mental, and social health for adults in the general population and those living with a chronic condition. PROMIS scores are reported as T scores ranging from 0-100. A higher PROMIS T-score represents more of the concept being measured. For negatively-worded concepts like Anxiety, a T-score of 60 is one SD worse than average. By comparison, an Anxiety T-score of 40 is one SD better than average. However, for positively-worded concepts like Physical Function-Mobility, a T-score of 60 is one SD better than average while a T-score of 40 is one SD worse than average. | Yearly for 3 years | |
Secondary | Co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS): Compass 31 | Investigators will compare co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS) using COMPASS31. The COMPASS31 contains 31 questions with Likert scales ranging in length from 2 to 6 items with higher scores indicating increased severity. COMPASS31 provides raw scores and standardized scores providing a total weighted score (0-100) of severity. The scale yields 6 subscales and a total score as follows: Orthostatic intolerance (4-10), Vasomotor (3-6); Secretomotor (4-7); Gastrointestinal (12-28); Bladder (3-9); Pupillomotor (5-15); Total (31-75) | Yearly for 3 years | |
Secondary | Co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS): Menstrual Distress Questionnaire | Investigators will compare co-morbidities in women with and without Generalized joint Hypermobility Syndrome Disorder/ hypermobile Ehlers-Danlos Syndrome (G-HSD/hEDS)using the Menstrual Distress Questionnaire. This is a 21-element survey (ENDOPAIN 4D) which measures the gynecological and pelvic pain symptoms associated with periods. Each question is on a 11-point Likert scale with higher scores reflecting more severe symptoms or symptoms that most closely resemble the description. | Yearly for 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02934789 -
Effectiveness of Truclear on Patient Quality of Life
|
N/A | |
Completed |
NCT02925494 -
An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
Recruiting |
NCT04959396 -
IUB SEAD RED (Revolutionary Endometrial Ablation Device Study
|
N/A | |
Active, not recruiting |
NCT04778072 -
A Clinical Study on Adherence and Efficacy of Different Doses of Active Iron in Treatment Resistant Subjects
|
N/A | |
Terminated |
NCT05026502 -
A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules
|
||
Recruiting |
NCT06064851 -
Delivering Transcutaneous Auricular Neurostimulation to Reduce Heavy Menstrual Bleeding in Von Willebrand Disease Patients
|
N/A | |
Terminated |
NCT04132349 -
Ulipristal Acetate in Symptomatic Uterine Fibroid
|
Phase 4 | |
Completed |
NCT00386308 -
Efficacy and Safety Study of XP12B in Women With Menorrhagia
|
Phase 3 | |
Completed |
NCT03412890 -
LIBERTY EXTENSION: Efficacy and Safety Extension Study of Relugolix in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
Active, not recruiting |
NCT04477837 -
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
|
||
Completed |
NCT05176496 -
A Study Called Champion-HMB to Learn More About Females With Heavy Menstrual Bleeding and Available Treatments to Enable Earlier Diagnosis and to Predict Courses of Treatment
|
||
Completed |
NCT01431326 -
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
|
||
Completed |
NCT00401193 -
Efficacy and Safety of XP12B in Women With Menorrhagia
|
Phase 3 | |
Completed |
NCT03317795 -
Treatment of Heavy Menstrual Bleeding in Women With Uterine Fibroids
|
Phase 4 | |
Completed |
NCT02943655 -
Treatment of Heavy and/or Prolonged Menstrual Bleeding Without Organic Cause
|
Phase 3 | |
Completed |
NCT03070951 -
Efficacy and Safety of OBE2109 in Subjects With Heavy Menstrual Bleeding Associated With Uterine Fibroids
|
Phase 3 | |
Completed |
NCT05406960 -
Therapeutic Effect of Herbal Infusion on Menometrorrhagia
|
N/A | |
Not yet recruiting |
NCT05079815 -
Heavy Menstrual Bleeding and Iron Deficiency Anemia
|
||
Active, not recruiting |
NCT02449304 -
Evaluation of 4th Generation Bipolar Radiofrequency Endometrial Ablation Device
|
Phase 4 | |
Terminated |
NCT02001324 -
HMB- Data Collection Methods
|
N/A |